Homeopathic Regulatory Evaluation Stocked With FDA Concerns, Industry Answers
This article was originally published in The Tan Sheet
Executive Summary
The industry wants FDA to consider that a fraction of poison control reports are for homeopathics compared to other drugs and the agency’s current enforcement authorities maintain compliance in manufacturing and marketing the products. FDA is considering whether to maintain its policy that recognizes an ingredient’s inclusion in the HPUS monograph as pre-market approval.
You may also be interested in...
Hyland's Argues Class Action Trips On State Laws Despite 'Artful Pleading'
Hyland’s says a class action complaint alleging deceptive business practices and false advertising for its baby products is not suitable to represent a class of consumers outside New York. But the plaintiffs argue that the issue over class suitability should be considered during the certification stage.
Hyland's Argues Class Action Trips On State Laws Despite 'Artful Pleading'
Hyland’s says a class action complaint alleging deceptive business practices and false advertising for its baby products is not suitable to represent a class of consumers outside New York. But the plaintiffs argue that the issue over class suitability should be considered during the certification stage.
Homeopathic Advertising Offers Slim Target For FTC Scrutiny – Industry
OTC homeopathic brands rely largely on word-of-mouth advertising from consumers’ friends and family members about their products’ safety and efficacy, stakeholders say at an FTC workshop. Consumers trust homeopathic OTCs even if they don’t understand products’ formulations, they say.